Clinical Trial Update: A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of VS-5584 in combination with VS-6063 for relapsed malignant mesothelioma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• VS-5584
• VS-6063 (defactinib)

Snippet

Sponsor: Verastem, Inc. | Conditions: Relapsed Malignant Mesothelioma | Phase 1 | Status: TERMINATED